Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26820 | 0.83 | HPGD (0.54) | HPGDDAOHCAR2 | |
| SCHEMBL15981916 | 0.81 | HPGD (0.52) | HPGDLMNAMAPTKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL27727584 | 0.81 | HPGD (0.52) | HPGDDAOHCAR2 | |
| SCHEMBL5013388 | 0.81 | HPGD (0.52) | HPGDSMN1; SMN2TSHRLMNAMAPT | |
| SCHEMBL17928435 | 0.78 | HPGD (0.49) | HPGDCYP3A4SMN1; SMN2LMNAMAPT | |
| SCHEMBL25449 | 0.77 | MAPK1 (0.57) | HPGDSMN1; SMN2MAPTKMT2ADYRK1A | |
| SCHEMBL6305513 | 0.77 | HPGD (0.49) | HPGDLMNAKMT2AALDH1A1DYRK1A | |
| SCHEMBL14620257 | 0.77 | HPGD (0.49) | HPGDMAPTALDH1A1DYRK1ADAO | |
| SCHEMBL18680106 | 0.77 | HPGD (0.49) | HPGDSMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL13248190 | 0.75 | HPGD (0.56) | HPGDTSHRMAPTBLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260056191-A1 | POLYMERS AND CONJUGATES COMPRISING THE SAME | VENTANA MEDICAL SYSTEMS, INC. (US) | 2026-02-26 | — | — | US | claimed |
| US-20240123045-A1 | NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS | BRENUS PHARMA (FR) | 2024-04-18 | — | — | US | claimed |
| EP-4297874-A1 | NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS | BRENUS PHARMA (FR) | 2024-01-03 | — | — | EP | claimed |
| WO-2022180251-A1 | NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS | BRENUS PHARMA (FR) | 2022-09-01 | — | — | WO | claimed |
| US-11079372-B2 | Polymers and conjugates comprising the same | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-08-03 | — | — | US | claimed |
| US-10775281-B2 | Polymer stabilization of chromogen solutions | VENTANA MEDICAL SYSTEMS, INC. (US) | 2020-09-15 | — | — | US | claimed |
| EP-2686438-B1 | A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFOR | VENTANA MED SYST INC (US) | 2018-04-18 | — | — | EP | claimed |
| EP-3201628-A2 | POLYMERS AND CONJUGATES COMPRISING THE SAME | Ventana Medical Systems, Inc. (US) | 2017-08-09 | — | — | EP | claimed |
| US-20170205399-A1 | POLYMERS AND CONJUGATES COMPRISING THE SAME | VENTANA MEDICAL SYSTEMS, INC. | 2017-07-20 | — | — | US | claimed |
| WO-2016050913-A2 | POLYMERS AND CONJUGATES COMPRISING THE SAME | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-04-07 | — | — | WO | claimed |
| CN-103534359-A | A method of analyzing chromosomal translocations and a system therefore | VENTANA MED SYST INC | 2014-01-22 | — | — | CN | claimed |
| EP-4707404-A2 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | Ventana Medical Systems, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260056191-A1 | POLYMERS AND CONJUGATES COMPRISING THE SAME | VENTANA MEDICAL SYSTEMS, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-12553886-B2 | Polymers and conjugates comprising the same | VENTANA MEDICAL SYSTEMS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3492919-B1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003057676-A1 | 3,4-DI-SUBSTITUTED PYRIDAZINEDIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003031440-A1 | 3,4-DI-SUBSTITUTED MALEIMIDE COMPOUNDS AS CXC-CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12553886-B2 | Polymers and conjugates comprising the same | POLL, INCENP, POLI | HPGD 1904/4885CYP3A4 2768/4885SMN1; SMN2 1052/4885 |
| US-20260056191-A1 | POLYMERS AND CONJUGATES COMPRISING THE SAME | POLD1, POLL, INCENP | HPGD 1891/4885CYP3A4 2165/4885SMN1; SMN2 1392/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | HPGD 2843/4885CYP3A4 500/4885SMN1; SMN2 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.